The Klotho gene, discovered in 1997, encodes a protein that plays a pivotal role in regulating aging and longevity. Reduced Klotho expression is associated with multiple age-related diseases, including renal, cardiovascular, neurodegenerative, and metabolic disorders, leading to the notion that supplementation of the levels of Klotho may have a beneficial, or even a therapeutic, effect. Despite promising early stage results from recombinant and gene-based therapies, clinical translation has been hindered in part by the protein’s short half-life as well as the immune clearance of Klotho producing cells. This article reviews Klotho’s biological significance and therapeutic challenges, as well as introducing a novel encapsulation-based approach—Cell-in-a-Box® technology—as a proposed potential solution for sustained Klotho delivery. Encapsulated Klotho-producing cells may potentially enable continuous secretion, immune protection, and long-term efficacy, offering a transformative strategy for anti-aging and disease modification.
No takes yet. Share an insight, caveat, or question.
Günzburg et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: